There are some known lung cancer biomarkers such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase, ROS gene rearrangements or immunohistochemical expression of programmed death-ligand 1 (PD-L1) that significantly influenced clinical practice [4,5,6]. Here, EGFR is linked to lung carcinoma.